Canaccord lowered the firm’s price target on AdaptHealth (AHCO) to $13 from $14 and keeps a Buy rating on the shares. The firm said they maintain their rating although they expect it will be several quarters for catalysts to emerge to drive shares higher.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
- AdaptHealth price target lowered to $14 from $16 at Baird
- AdaptHealth Reports Q3 2024 Financial Results
- Morning Movers: GlobalFoundries and Apollo Global gain following Q3 results
- AdaptHealth revises FY24 revenue view to $ $3.22B-$3.26B, consensus $3.28B
- AdaptHealth reports Q3 EPS 15c, consensus 17c